Abstract
Introduction: New drugs for multiple myeloma have considerably increased the options for consecutive treatment lines in regular care. Official treatment guidelines still discuss several regimens per line, and therefore, current practice is of topical interest. Large cross-sectional studies revealed a greater than linear loss of patients reaching consecutive treatment lines of ever decreasing effectiveness. Methods: In a longitudinal approach, we analyzed data of all 145 multiple myeloma patients treated in our outpatient clinic in Germany between January 1, 2012, and December 31, 2019, using a time-to-event analysis with death as competitive risk. Results: The estimated incidences of reaching the 2nd, 3rd, 4th, and 5th lines of therapy were 88, 66, 44, and 30%, respectively. Median times to subsequent treatment lines were 34, 18, 14, 13, and 15 months, respectively. Discussion: Percentages of patients reaching later therapy lines were considerably greater than predicted by cross-sectional studies and median times after the 1st line did not suggest a further decrease in effectiveness, while use of new drug regimens was similar to that reported in cross-sectional studies. Conclusion: Effectiveness of later therapy lines appears to be underestimated by cross-sectional analyses, and the conveyed focus on 1st-line treatment for multiple myeloma needs to be scrutinized.
Journal Section:
Research Article
References
1.
Kazandjian
D
. Multiple myeloma epidemiology and survival: A unique malignancy
. Semin Oncol
. 2016
Dec
;43
(6
):676
–81
.
[PubMed]
1532-87082.
Kaatsch
P
, Spix
C
, Katalinic
A
, Hentschel
S
, Luttmann
S
, Waldeyer-Sauerland
M
, et al. Krebs in Deutschland für 2015/2016. 12 ed. Berlin2019
.3.
Costa
LJ
, Hari
PN
, Kumar
SK
. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity
. Leuk Lymphoma
. 2016
Dec
;57
(12
):2827
–32
.
[PubMed]
1029-24034.
Knauf
W
, Aldaoud
A
, Hutzschenreuter
U
, Klausmann
M
, Dille
S
, Wetzel
N
, et al.; and the TLN-Group (Tumour Registry Lymphatic Neoplasms)
. Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms
. Ann Hematol
. 2018
Dec
;97
(12
):2437
–45
.
[PubMed]
1432-05845.
Klausen
TW
, Gregersen
H
, Abildgaard
N
, Andersen
NF
, Frølund
UC
, Gimsing
P
, et al.. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials
. Leukemia
. 2019
Feb
;33
(2
):546
–9
.
[PubMed]
1476-55516.
Dimopoulos
MA
, Moreau
P
, Terpos
E
, Mateos
MV
, Zweegman
S
, Cook
G
, et al.. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
. HemaSphere
. 2021
Feb
;5
(2
):e528
.
[PubMed]
2572-92417.
Knauf
W
, Abenhardt
W
, Aldaoud
A
, Nusch
A
, Grugel
R
, Munz
M
, et al. Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncology research and treatment. 2014
;37(11):635-6, 38-44.8.
Raab
MS
, Cavo
M
, Delforge
M
, Driessen
C
, Fink
L
, Flinois
A
, et al.. Multiple myeloma: practice patterns across Europe
. Br J Haematol
. 2016
Oct
;175
(1
):66
–76
.
[PubMed]
1365-21419.
Yong
K
, Delforge
M
, Driessen
C
, Fink
L
, Flinois
A
, Gonzalez-McQuire
S
, et al.. Multiple myeloma: patient outcomes in real-world practice
. Br J Haematol
. 2016
Oct
;175
(2
):252
–64
.
[PubMed]
1365-214110.
Merz
M
, Kellermann
L
, Poenisch
W
, Tischler
HJ
, Kohnke
J
, Knauf
W
, et al.. Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey
. Ann Hematol
. 2017
Jun
;96
(6
):987
–93
.
[PubMed]
1432-058411.
Coriu
D
, Dytfeld
D
, Niepel
D
, Spicka
I
, Markuljak
I
, Mihaylov
G
, et al.. Realworld multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries.
Polish archives of internal medicine. 2018
Sep
28
;128(9):500-11.12.
Merz
M
, Patel
V
, Kutikova
L
, Lebioda
A
, Schoehl
M
, Kellermann
L
, et al.. Treatment Patterns in Patients (pts) with Refractory/Relapsed Multiple Myeloma (RRMM) in Germany between 2016 and 2018
. Blood
. 2019
;134
Supplement_1
:4734
–34
. 0006-497113.
Mohty
M
, Cavo
M
, Fink
L
, Gonzalez-McQuire
S
, Leleu
H
, Mateos
MV
, et al.. Understanding mortality in multiple myeloma: findings of a European retrospective chart review
. Eur J Haematol
. 2019
Aug
;103
(2
):107
–15
.
[PubMed]
1600-060914.
Raab
MS
, Fink
L
, Schoen
P
, Gonzalez-McQuire
S
, Flinois
A
, Cavo
M
, et al.. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016
. Br J Haematol
. 2019
Jun
;185
(5
):981
–4
.
[PubMed]
1365-214115.
Mohty
M
, Knauf
W
, Romanus
D
, Corman
S
, Verleger
K
, Kwon
Y
, et al.. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom
. Eur J Haematol
. 2020
Sep
;105
(3
):308
–25
.
[PubMed]
1600-060916.
Steinmetz
HT
, Singh
M
, Lebioda
A
, Gonzalez-McQuire
S
, Rieth
A
, Schoehl
M
, et al.. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany
. Oncol Res Treat
. 2020
;43
(9
):449
–59
.
[PubMed]
2296-526217.
Cavo
M
, Terpos
E
, Bargay
J
, Einsele
H
, Cavet
J
, Greil
R
, et al.. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe
. Expert Rev Hematol
. 2018
Mar
;11
(3
):219
–37
.
[PubMed]
1747-409418.
Rajkumar
SV
, Dimopoulos
MA
, Palumbo
A
, Blade
J
, Merlini
G
, Mateos
MV
, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
. Lancet Oncol
. 2014
Nov
;15
(12
):e538
–48
.
[PubMed]
1474-548819.
Greipp
PR
, San Miguel
J
, Durie
BG
, Crowley
JJ
, Barlogie
B
, Bladé
J
, et al.. International staging system for multiple myeloma
. J Clin Oncol
. 2005
May
;23
(15
):3412
–20
.
[PubMed]
0732-183X20.
Harousseau
JL
, Dreyling
M
, Group
EG
; ESMO Guidelines Working Group
. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
. Ann Oncol
. 2010
May
;21
Suppl 5
:v155
–7
.
[PubMed]
1569-804121.
Moreau
P
, San Miguel
J
, Ludwig
H
, Schouten
H
, Mohty
M
, Dimopoulos
M
, et al.; ESMO Guidelines Working Group
. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
. Ann Oncol
. 2013
Oct
;24
Suppl 6
:vi133
–7
.
[PubMed]
1569-804122.
Moreau
P
, San Miguel
J
, Sonneveld
P
, Mateos
MV
, Zamagni
E
, Avet-Loiseau
H
, et al.; ESMO Guidelines Committee
. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
. Ann Oncol
. 2017
Jul
;28
suppl_4
:iv52
–61
.
[PubMed]
1569-804123.
Andersen
PK
, Klein
JP
. Regression analysis for multistate models based on a pseudo-value approach, with applications to bone marrow transplantation studies
. Scand J Stat
. 2007
;34
(1
):3
–16
. 0303-689824.
Ferguson
AN
, Datta
S
, Brock
G
. msSurv: An R Package for Nonparametric Estimation of Multistate Models
. J Stat Softw
. 2012
;50
(14
):50
. 1548-7660© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
